Parnassus Investments LLC Buys 16,205 Shares of Insulet Corporation $PODD

Parnassus Investments LLC lifted its stake in Insulet Corporation (NASDAQ:PODD) by 10.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 166,904 shares of the medical instruments supplier’s stock after acquiring an additional 16,205 shares during the period. Parnassus Investments LLC owned 0.24% of Insulet worth $47,441,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. IFM Investors Pty Ltd raised its stake in shares of Insulet by 4.5% in the 4th quarter. IFM Investors Pty Ltd now owns 15,377 shares of the medical instruments supplier’s stock valued at $4,371,000 after acquiring an additional 657 shares in the last quarter. Graetz Wealth LLC bought a new position in Insulet in the 4th quarter worth approximately $220,000. Mattson Financial Services LLC increased its position in Insulet by 11.5% in the 4th quarter. Mattson Financial Services LLC now owns 6,487 shares of the medical instruments supplier’s stock worth $1,844,000 after buying an additional 670 shares during the period. Scholtz & Company LLC increased its position in Insulet by 15.3% in the 4th quarter. Scholtz & Company LLC now owns 12,976 shares of the medical instruments supplier’s stock worth $3,688,000 after buying an additional 1,718 shares during the period. Finally, Meeder Asset Management Inc. increased its position in Insulet by 49.7% in the 4th quarter. Meeder Asset Management Inc. now owns 1,605 shares of the medical instruments supplier’s stock worth $456,000 after buying an additional 533 shares during the period.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $149.19 on Friday. Insulet Corporation has a 1-year low of $140.63 and a 1-year high of $354.88. The firm has a market capitalization of $10.33 billion, a PE ratio of 34.70, a PEG ratio of 1.19 and a beta of 1.13. The business’s 50 day moving average is $171.07 and its 200-day moving average is $233.25. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same quarter last year, the firm earned $1.02 EPS. Insulet’s revenue for the quarter was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Sell-side analysts predict that Insulet Corporation will post 6.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on PODD shares. UBS Group set a $219.00 price target on Insulet in a research report on Thursday. Wall Street Zen raised Insulet from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Jefferies Financial Group dropped their price target on Insulet from $400.00 to $360.00 in a research report on Thursday, May 7th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $280.00 price target on shares of Insulet in a research report on Wednesday, May 27th. Finally, Canaccord Genuity Group dropped their price target on Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $240.78.

Insider Buying and Selling at Insulet

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The shares were bought at an average price of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.36% of the company’s stock.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.